Biomednewsbreaks - Aditxt Inc. (NASDAQ: ADTX) Explores IPO For Pearsanta To Advance Early Cancer Detection

(MENAFN- Investor Brand Network) Aditxt (NASDAQ: ADTX) a social innovation platform dedicated to advancing health innovations, announced its Board of Directors has authorized management to explore an initial public offering (“IPO”) for its subsidiary, Pearsanta, Inc., in 2025. Pearsanta, a precision diagnostics company leveraging its proprietary Mitomic® technology platform for early cancer detection, aims to use the IPO proceeds to accelerate growth and expand market presence. Aditxt CEO Amro Albanna highlighted Pearsanta's mission to tackle the global challenge of cancer, noting the launch of the Mitomic® platform as a key milestone in advancing transformative health innovations. Pearsanta President Chris Mitton emphasized the IPO's potential to bring its technology to the global stage, enabling faster commercialization and empowering clinicians with tools for earlier and more accurate diagnoses, positioning Pearsanta to make a meaningful impact on global healthcare outcomes.

To view the full press release, visit

About Aditxt Inc.

Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to“Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women's health. For these, Aditxt has entered into an arrangement agreement with
Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) , which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt's mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit
.

NOTE TO INVESTORS:
The latest news and updates relating to ADTX are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN13012025000224011066ID1109085565